Advance Sentry Corporation · Viral Genetic Diagnostics

Early detection of viral-related cancers — non-invasive and precise.

Advance Sentry is a Canadian company specialising in viral genetic-based diagnostic technology. Its first product, NP Screen™, is the only FDA-approved non-invasive method for the early detection of nasopharyngeal carcinoma. Interblock is guiding Advance Sentry to the public markets.

Our mission

To safeguard patients’ health through the early detection of viral-related cancers — at the onset of tumour transformation — improving treatment response and outcomes.

NP Screen™

The highest-accuracy early screen for nasopharyngeal carcinoma.

Simple, non-invasive, painless — and the only FDA-approved method of its kind on the market.

Dr. Raymond Ng

Led the medical team through the entire R&D process — clinical trial design, planning and regulatory approval. A Fellow in Otolaryngology – Head and Neck Surgery (Royal College of Physicians and Surgeons of Canada, 1993) with over 30 years of experience, involved in the original EBV DNA research and developer of the trans-oral brushing biopsy method for the nasopharynx.

Dr. John Phillips

Oversees product design, development and quality assurance across all regulatory submissions. A qualified plastic and craniofacial surgeon (MD 1980; Fellow, Royal College, 1985) with 30+ years of surgical experience, an extensive publication record and deep expertise launching medical devices in North America.

0% accuracy
0+ clinical trials
0Countries — Canada & HK
0FDA-approved of its kind

Their website

Explore NP Screen™ and the full Advance Sentry story.

Visit advancesentry.com ↗

Part of the Interblock portfolio

Bringing life-saving diagnostics to the public markets.

Talk to our team →